By Kamran Zamanian, Ph.D., and Jesse Spicer, iData Research Inc.

Since the launch of LifeCell’s AlloDerm product in the United States in 1994, the use of biologic tissue matrices for soft tissue reinforcement and regeneration has grown considerably. Synthetic mesh has historically been used in the larger soft tissue markets, such as hernia repair, and it continues to be the standard choice, especially for more routine procedures, like inguinal hernia repair. However, it hasn’t experienced growth comparable to biologic soft tissue grafts in recent years.

While the market for biologics has been increasing consistently in the U.S., and will continue to do so at the expense of the synthetic mesh market, the situation in Europe differs dramatically. There are a multitude of factors at play that have resulted in…